
DCTs can be a great tool for small-to-midsize pharma and biotech companies despite misconceptions of them being advantageous for only Big Pharma.
DCTs can be a great tool for small-to-midsize pharma and biotech companies despite misconceptions of them being advantageous for only Big Pharma.
Researchers aren't taking full advantage of advances in trial technologies. A lack of clarity in the current version of the International Council for Harmonization "Guidelines for Good Clinical Practice", could be the problem.
Published: February 13th 2025 | Updated: March 4th 2025
Published: February 19th 2025 | Updated: February 26th 2025
Published: March 24th 2023 | Updated:
Published: April 28th 2021 | Updated:
Published: July 26th 2024 | Updated:
Published: January 31st 2024 | Updated: